Research programme: irritable bowel syndrome therapeutics - Asterand

Drug Profile

Research programme: irritable bowel syndrome therapeutics - Asterand

Alternative Names: PGN1091; PGN1164; R1 programme - Asterand

Latest Information Update: 13 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asterand plc
  • Class
  • Mechanism of Action Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 13 Feb 2007 Discontinued - Preclinical for Irritable bowel syndrome in United Kingdom (PO)
  • 30 Jan 2006 Pharmagene has merged with Asterand to form Asterand plc
  • 29 Apr 2005 Development of PGN 1164 has been discontinued
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top